News

November 11, 2019November 11, 2019

Bimekizumab Found to be Safe and Show Sustained Efficacy for AS Treatment in Phase 2b Trial

News

Treatment with the experimental therapy bimekizumab is safe and shows sustained efficacy over 48 weeks in people with ankylosing spondylitis (AS), data from a Phase 2b trial show. In ... Read more

November 7, 2019November 7, 2019

Continuous Use of NSAIDs Increases Hypertension Risk in AS Patients, Study Suggests

News

Continuous use of non-steroidal anti-inflammatory drugs (NSAIDs) increases the risk of hypertension by 12% in people with ankylosing spondylitis (AS), a prospective study suggests. The study, “Nonsteroidal Anti-inflammatory Drug ... Read more

November 4, 2019November 4, 2019

Women Stop Using TNF Inhibitors Earlier and Switch More Often Than Do Men, Dutch Study Reports

News

Women with ankylosing spondylitis (AS) stay with TNF inhibitor treatment for significantly shorter periods than men, mostly due to ineffectiveness, and they are at higher risk of developing infections while on ... Read more

October 31, 2019October 31, 2019

Likelihood of Gout May Be More Common in AS Patients, Study Reports

News

Gout —a common, painful form of arthritis that causes swollen, red, hot, and stiff joints — may be more common in people with ankylosing spondylitis (AS) than in the general ... Read more

October 28, 2019October 28, 2019

Higher Dosage of Cosentyx for Ankylosing Spondylitis Approved in Europe

News

The European Commission has approved a label update for Cosentyx (secukinumab) that will allow healthcare providers to prescribe doses of up to 300 mg — twice what was previously ... Read more

October 24, 2019October 24, 2019

Dutch Study Examines Factors that Contribute to Depression in AS

News

Men, people who are employed, have a lower income, perceive less control over their lives, and are less satisfied about their social roles, are among those with ankylosing spondylitis ... Read more

October 21, 2019October 21, 2019

Xeljanz Reduces Spinal Inflammation in One-third of AS Patients, Phase 2 Trial Shows

News

Treatment with Xeljanz (tofacitinib citrate) led to a clinically meaningful reduction in spinal and sacroiliac joint inflammation in approximately one-third of ankylosing spondylitis (AS) patients taking part in a ... Read more

October 17, 2019October 17, 2019

SAA Joins with PatientPoint to Improve Disease Understanding, Treatment at Rheumatology Centers

News

The Spondylitis Association of America (SAA) and PatientPoint are working to improve spondylitis education, treatment, and support information at rheumatology practices nationwide. The partnership will utilize PatientPoint’s platform, designed to educate and empower patients, ... Read more

October 14, 2019October 14, 2019

Ankylosing Spondylitis Psoriasis, Axial Psoriatic Arthritis Unrelated, Study Says

News

Psoriasis in ankylosing spondylitis (AS) patients is not related to axial psoriatic arthritis (PsA), a type of psoriasis causing lower back inflammation and pain similar to AS, a new ... Read more

October 10, 2019October 10, 2019

Anti-TNF Therapy Slows Down AS Progression and Bone Loss, Study Says

News

Anti-TNF therapies can halt disease progression and bone loss, and are associated with clinical improvement in people with ankylosing spondylitis after one year of treatment, a study shows. The ... Read more

Pin It on Pinterest